Genetics and Cancer · uk
Screening 5,000 Breast Cancer Risk Variants Identifies 709 Gene Regulation Clues
Which genetic differences merely accompany breast cancer risk, and which may actually alter how cells function? A large-scale experiment has narrowed the search and brought CCDC88C into focus, but key evidence is still needed before the findings can be applied to individual risk testing or treatment.
Finding locations in the human genome associated with breast cancer risk does not mean understanding how the disease develops. Many genetic variants lie in regions that do not directly encode proteins and may exert their effects by adjusting gene activity. Using large-scale cell experiments, a team at the Institute of Cancer Research, London, has now identified 709 variants with significant differences in regulatory activity from 5,116 candidate variants, providing a clearer direction for further investigation.
The study was published online in *Human Genetics and Genomics Advances* on September 17, and the institute presented the findings on November 5. Building on existing genome-wide association studies and fine-mapping analyses, the team sought to overcome a challenge in genetics: neighboring variants are often inherited together, making it difficult to distinguish which variants have functional effects even when a stretch of DNA is associated with disease risk.
The researchers used a lentivirus-based massively parallel reporter assay to introduce DNA fragments carrying different versions of the variants into T-47D breast cancer cells and compare their effects on reporter gene activity. They found significant differences between the reference and alternative alleles of 709 variants across 140 risk regions. This indicates that some candidate variants can indeed alter regulatory activity under the experimental conditions and warrant priority for further investigation.
Among these, the team investigated rs7153397 in the 14q32.11 region of chromosome 14. Together with follow-up functional experiments, the results pointed to CCDC88C as a gene that may be regulated by this variant, suggesting a possible link from genetic variation to gene expression and breast cancer risk. However, this mechanism still requires further evidence and does not establish that the variant has been proven to cause breast cancer.
The study also examined patient tumor data. The team found that CCDC88C expression was higher in estrogen receptor-positive (ER-positive) breast cancers than in receptor-negative tumors. Among ER-positive patients, higher expression was also associated with better survival. This association suggests that its role may involve breast cancer subtypes, but it does not mean that increasing CCDC88C expression would improve the disease, nor does it directly establish a treatment direction.
The limitations of the screening results are equally important. Reporter gene experiments measure regulatory effects in specific cells and under a particular experimental design; they are not sufficient to fully reproduce how genes function in human tissues. The 709 variants therefore do not represent 709 confirmed causes of cancer. Nor can variants that showed no significant effect be ruled out as potentially having effects in other cells or under other biological conditions.
The study’s most concrete contribution at this stage is to prioritize a complex set of risk signals for experimental investigation. The next steps are to clarify how each variant acts in different breast cancer subtypes and cells, and to further validate the biological role of CCDC88C. This work may gradually fill gaps in our understanding of the mechanisms behind genetic risk, but the study itself has not established a new test for clinical use or demonstrated an improvement in individual risk prediction.